Insurf

Insurf takes a genuinely different approach: instead of a point solution for cost comparison or prior auth, it builds a graph that links every decision—plan choice, prior auth, appeal outcome—into a living dataset that gets smarter over time. That's a smart long-term bet, but it means the value depends on data accumulation, which only works if the platform actually gets used. Right now, the 'Pre–Demo Day' pilot is limited to specialty practices and lasts only 90 days. Denial rates in ACA plans run 13-35% per insurer, so the pain point is real. If Insurf can show that its automated, physician-attested appeals actually reduce denials and accelerate cash flow, it could become essential infrastructure. But the product is early, the customer base is narrow, and the graph flywheel hasn't been proven in production. We'd pick Insurf if you're a specialty practice with high denial volume and are willing to co-build during the pilot. We'd pass if you need a mature, scaled solution today. Compared to point tools like Zocdoc for comparison or Xsolis for prior auth, Insurf is more ambitious but riskier. Buyers should also note that pricing isn't public—expect to negotiate.